COVID-19 vaccine and mRNA technology: spreading the knowledge

The client
A publicly traded leading Pharmaceutical and Biotechnology company based in Cambridge (USA) pioneering a new class of medicines made of mRNA and focusing on RNA therapeutics, primarily mRNA vaccines.

The project
- The challenges
The Biotechnology company has video series about their FDA (the U.S. Food and Drug Administration) and EMA (the European Medicines Agency)-approved mRNA-based vaccine indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.
That content should reach the relevant Brazilian communities of scientists, sharing details regarding the mRNA technology platform — from mRNA engineering to the manufacturing process — and the vaccine itself — mechanism of action, safety and efficacy and clinical trials data from various populations.

- The solution
Translation and localization services.

- The content
Speaker’s video scripts and visuals content.

The outcome
Video scripts and visuals content translated and localized from English into Brazilian Portuguese and linguistically appropriate for use within relevant Brazilian communities of scientists, spreading the knowledge regarding mRNA technology and a vaccine that eventually would help to mitigate the pandemic situation of COVID-19.
Ultimately, this video series in Brazilian Portuguese has also been part of the story of the biotechnology company, which has been in the spotlight in the industry for their rapid expansion due to the above-mentioned mRNA vaccine, currently under review by the Brazilian National Health Surveillance Agency (ANVISA), and new tools and technologies to come.